Marko Hocevar

Marko Hocevar

Auto-generated profile, based on publicly available information

Marko Hocevar

Institute of Oncology, Ljubljana, Slovenia

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2005 in European Radiology
Verified
Journal Article
Closed access
PDF file
MPMaja Podkrajsek
Maja Podkrajsek
MMMaja Marolt Music
Maja Marolt Music
MKMaksimiljan Kadivec
Maksimiljan Kadivec
JZJanez Zgajnar
Janez Zgajnar
NBNikola Besic
Nikola Besic
MHMarko Hocevar
Marko Hocevar

1 January 2017 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MHM. Hocevar
M. Hocevar
LLL. Lezaic
L. Lezaic
SRS. Rep
S. Rep
KZK. Zaletel
K. Zaletel
TKT. Kocjan
T. Kocjan
BPB. Peric
B. Peric

27 November 2015 in Radiology and Oncology
Verified
Journal Article
Open access
SRSebastijan Rep
Sebastijan Rep
LLLuka Lezaic
Luka Lezaic
TKTomaz Kocjan
Tomaz Kocjan
MPMarija Pfeifer
Marija Pfeifer
MSMojca Jensterle Sever
Mojca Jensterle Sever
MHMarko Hocevar
Marko Hocevar
Parathyroid adenomas, the most common cause of primary hyperparathyroidism, are benign tumours which autonomously produce and secrete parathyroid hormone. [(18)F]-fluorocholine (FCH), PET marker of cellular proliferation, was recently demonstrated to accumulate in lesions representing enlarged parathyroid tissue; however, the optimal time to perform FCH PET/CT after FCH administration is not known. The aim of this study was to determine the optimal scan time of FCH PET/CT in patients with primary hyperparathyroidism. 43 patients with primary hyperparathyroidism were enrolled in this study. A triple-phase PET/CT imaging was performed five minutes, one and two hours after the administration of FCH. Regions of interest (ROI) were placed in lesions representing enlarged parathyroid tissue and thyroid tissue. Standardized uptake value (SUVmean), retention index and lesion contrast for parathyroid and thyroid tissue were calculated. Accumulation of FCH was higher in lesions representing enlarged parathyroid tissue in comparison to the thyroid tissue with significantly higher SUVmean in the second and in the third phase (p < 0.0001). Average retention index decreased significantly between the first and the second phase and increased significantly between the second and the third phase in lesions representing enlarged parathyroid tissue and decreased significantly over all three phases in thyroid tissue (p< 0.0001). The lesion contrast of lesions representing enlarged parathyroid tissue and thyroid tissue was significantly better in the second and the third phase compared to the first phase (p < 0.05). According to the results the optimal scan time of FCH PET/CT for localization of lesions representing enlarged parathyroid tissue is one hour after administration of the FCH.

1 December 2004 in Melanoma Research
Verified
Journal Article
Closed access
MHMarko Hocevar
Marko Hocevar
MBMatej Bracko
Matej Bracko
APAna Pogacnik
Ana Pogacnik
BVBarbara Vidergar-Kralj
Barbara Vidergar-Kralj
NBNikola Besic
Nikola Besic
MMMaja Marolt Music
Maja Marolt Music
Sentinel lymph node (SLN) biopsy is the most effective method to nodally stage patients with melanoma. However, SLN metastases are an indication for a complete regional lymphadenectomy. The aim of this study was to evaluate the ability of ultrasound (US) and US-guided fine needle aspiration biopsy (US-FNAB) to reduce the number of patients requiring a second surgical procedure. Fifty-seven patients with melanoma underwent preoperative US of the regional lymph nodes before SLN biopsy. In patients with US malignant lymph nodes, US-FNAB was performed. Only patients with cytologically proven lymph node metastases proceeded directly to a complete regional lymphadenectomy, whereas, in all others, SLN biopsy was performed. Fourteen patients (25%) had metastases in the regional lymph nodes. There were 40 benign and 17 malignant US results. US-FNAB was performed in 14 patients. It was positive in three, negative in nine and inadequate sampling was obtained in two. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of US were 71%, 84%, 59% and 90%, respectively. US of the regional lymph nodes with US-FNAB enables the safe selection of patients who should proceed directly to a complete regional lymphadenectomy. However, the sensitivity and PPV of the method are low.

2 August 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
BPBarbara Perić
Barbara Perić
IZIvana Zagar
Ivana Zagar
SNSrdjan Novaković
Srdjan Novaković
JZJanez Zgajnar
Janez Zgajnar
MHMarko Hocevar
Marko Hocevar
Background: Increased level of serum S100B can serve as a marker of metastatic spread in patients with cutaneous melanoma (CM). In patients with elevated S100 B and/or clinical signs of disease progression PET-CT scan is a valuable tool for discovering metastases and planning treatment. The aims of this study were to determine whether regular measurements of serum S100B are a useful tool for discovering patients with CM metastases and to evaluate the diagnostic value of PET-CT during the follow-up. Methods: From September 2007 to February 2010, 115 CM patients included in regular follow up at the Institute of Oncology Ljubljana were appointed to PET-CT. There were 82 (71.3%) patients with clinical signs of disease progression and 33 (28.7%) asymptomatic patients with two subsequent elevated values of S100B. Sensitivity, specificity, positive and negative predictive value (PPV, NPV) of S100B and PET-CT were calculated using standard procedures. Results: Disease progression was confirmed in 81.7% of patients (in 86.5% of patients with clinical signs of disease progression and in 69.7% of asymptomatic patients with elevated S100B). Sensitivity, specificity, PPV and NPV of S100B was 33.8%, 90.9%, 96.0% and 17.5% in patients with clinical signs of disease progression. In 20.0% of patients increased serum S100B was the only sign of disease progression. Sensitivity and PPV of S100 in this group of patients were 100.0% and 69.7%. With PET-CT disease progression was diagnosed in 84.2% of symptomatic patients and in 72.7% of asymptomatic patients with elevated S100B. The sensitivity, specificity, PPV and NPV of PET-CT for symptomatic patients was 98.5%, 90.9%, 98.5% and 90.9% and 100%, 90.0%, 95.8% and 100% for asymptomatic patients with elevated S100. Conclusions: Measurements of serum S100B during regular follow-up of patients with CM are a useful tool for discovering disease progression in asymptomatic patients. The value of its use increases if measurements are followed by extended whole body PET-CT.

10 September 2008 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
MKMateja Krajc
Mateja Krajc
ETErik Teugels
Erik Teugels
JZJanez Zgajnar
Janez Zgajnar
GGGuido Goelen
Guido Goelen
NBNikola Besic
Nikola Besic
JGJacques De Grève
Jacques De Grève
Both recurrent and population specific mutations have been found in different areas of the world and more specifically in ethnically defined or isolated populations. The population of Slovenia has over several centuries undergone limited mixing with surrounding populations.